German pharma giants slash billions in investments amid health policy reforms

The German pharmaceutical sector faced a sharp reversal of investment plans in early June 2026. Boehringer Ingelheim announced it would cancel €900 million of projects slated for 2027‑2030, citing the German government's health‑spending cuts and rising mandatory manufacturer rebates that undermine planning certainty. At the same time, U.S. firm Eli Lilly said it would halve its €2.5 billion investment in a new production site in Alzey, Rhineland‑Palatinate, limiting the project to a minimum‑scope version.

Both companies pointed to the upcoming GKV‑Beitragsstabilisierungsgesetz, which will increase rebates paid by drug makers to statutory health insurers and tighten overall health‑budget constraints. A spokesperson for the Federal Ministry of Health described the decisions as “regrettable” but affirmed that the German market remains attractive and that a dedicated pharma strategy is being prepared.

Jasmina Kirchhoff, an expert at the Institut der deutschen Wirtschaft, called the moves “clear warning shots” for Germany’s pharma location, warning of a systemic risk that could affect other firms and signal to foreign investors that the regulatory climate is becoming hostile. She urged ministries to resolve the conflict between health‑policy cost‑control and the economic imperative of maintaining Germany as Europe’s leading pharmaceutical hub.